Regression of fibrous dysplasia in response to denosumab therapy: A report of two cases

We present two patients with fibrous dysplasia who showed a decrease in lesional size and activity after denosumab therapy. Both patients also experienced a reduction in pain and bone turnover markers, which had not been accomplished during previous bisphosphonate therapy. These cases highlight the...

Full description

Saved in:
Bibliographic Details
Published inBone Reports Vol. 14; p. 101058
Main Authors Meier, Maartje E., van der Bruggen, Wouter, van de Sande, Michiel A.J., Appelman-Dijkstra, Natasha M.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.06.2021
Elsevier
Subjects
Antiresorptive
Case Report
Denosumab
Fibrous dysplasia
McCune Albright syndrome
Nuclear imaging
Antiresorptive
Denosumab
Fibrous dysplasia
Nuclear imaging
McCune Albright syndrome
Online AccessGet full text

Cover

More Information
Summary:We present two patients with fibrous dysplasia who showed a decrease in lesional size and activity after denosumab therapy. Both patients also experienced a reduction in pain and bone turnover markers, which had not been accomplished during previous bisphosphonate therapy. These cases highlight the potential of denosumab to decrease lesional size in fibrous dysplasia. This finding has been reported in mice, but not in humans. Denosumab may be considered when bisphosphonates are not tolerated or not effective (enough), or in severe cases as neoadjuvant therapy to improve surgical possibilities and outcome. In addition, these results show that Na[18F]F PET-CT is suitable for detecting change in each fibrous dysplasia lesion distinctively.
ISSN:2352-1872
2352-1872
DOI:10.1016/j.bonr.2021.101058